Abstract
BackgroundPatients (pts) with peripheral SpA (pSpA) manifest with peripheral arthritis, enthesitis, and/or dactylitis. ABILITY-2 has demonstrated the efficacy of adalimumab (ADA) vs. placebo (PBO) over 12 weeks (wk). No long-term...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
